Quick Answer
Zenas BioPharma, Inc. reported Stockholders Equity of $242.14 million for fiscal year 2025.
Zenas BioPharma, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $242.14M | -22.5% |
| 2024 | $312.46M | +238.4% |
| 2023 | -$225.72M | -17.4% |
| 2022 | -$192.29M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $196.43M | -45.4% | -18.0% |
| June 30, 2025 | $239.63M | +183.0% | -15.7% |
| March 31, 2025 | $284.32M | +212.6% | -9.0% |
| December 31, 2024 | $312.46M | +238.4% | -13.1% |
| September 30, 2024 | $359.44M | +277.7% | +224.5% |
| June 30, 2024 | -$288.78M | -20.9% | -14.4% |
| March 31, 2024 | -$252.50M | -19.9% | -11.9% |
| December 31, 2023 | -$225.72M | -17.4% | -11.6% |
- Zenas BioPharma, Inc. showed a decrease of -22.5% in Stockholders Equity compared to the prior fiscal year.
- Over the 2022–2025 period, Zenas BioPharma, Inc.’s stockholders equity has grown by 225.9% (from -$192.29 million to $242.14 million).
- The most recent figure is from Zenas BioPharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 16, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: